Indeed, determining the expression of hormone receptors, as well as the human epidermal growth factor receptor 2 (HER2) or the programmed death-ligand 1 (PD-L1) status, is crucial to paving the way for personalized targeted therapy, especially in cases of advanced/metastatic disease or recurrence [117]. The gene discussed is ERBB2; the disease is metastatic neoplasm.